Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

187.98USD
24 Sep 2018
Change (% chg)

$-3.33 (-1.74%)
Prev Close
$191.31
Open
$190.11
Day's High
$192.17
Day's Low
$187.74
Volume
398,450
Avg. Vol
499,666
52-wk High
$217.00
52-wk Low
$142.83

Chart for

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $63,808.76
Shares Outstanding(Mil.): 339.44
Dividend: 0.72
Yield (%): 1.53

Financials

  AGN.N Industry Sector
P/E (TTM): -- 30.48 32.69
EPS (TTM): -12.52 -- --
ROI: -3.65 13.04 12.72
ROE: -5.92 14.99 14.85

Allergan must face antitrust lawsuits over Restasis - judge

A federal judge on Tuesday rejected Allergan PLC's bid to dismiss lawsuits alleging that the drugmaker violated antitrust laws by improperly trying to delay U.S. regulatory approval of generic competitors for its dry-eye medication Restasis.

Sep 18 2018

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Sep 14 2018

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

Sep 14 2018

UPDATE 1-FDA rejects Allergan's Esmya fibroid treatment

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

Aug 21 2018

FDA declines to approve Allergan's Esmya

Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

Aug 21 2018

FDA declines to approve Allergan's Esmya

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

Aug 21 2018

Deals of the day-Mergers and acquisitions

Aug 3 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Friday:

Aug 03 2018

Deals of the day-Mergers and acquisitions

Aug 3 The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday:

Aug 03 2018

Spain's Almirall bets on dermatology with $650 million U.S. deal

Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

Aug 03 2018

UPDATE 1-Spain's Almirall bets on dermatology with $650 mln U.S. deal

Aug 3 Spanish pharmaceutical company Almirall said on Friday it had agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

Aug 03 2018

Earnings vs. Estimates